fluorouracil has been researched along with Menopause, Premature in 4 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Menopause, Premature: The premature cessation of menses (MENSTRUATION) when the last menstrual period occurs in a woman under the age of 40. It is due to the depletion of OVARIAN FOLLICLES. Premature MENOPAUSE can be caused by diseases; OVARIECTOMY; RADIATION; chemicals; and chromosomal abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare dose-intensified epirubicin monotherapy with a standard sequential regimen, patients with primary breast cancer and > or =10 involved axillary nodes were randomised to either four 21-day cycles of epirubicin 120 mg/m(2) (E120; n=202) or four 21-day cycles of epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) (EC) followed by three 28-day cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF; n=209)." | 9.14 | Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. ( Ataseven, B; Conrad, B; Eiermann, W; Graf, E; Hilfrich, J; Kaufmann, M; Loibl, S; Massinger-Biebl, H; Schumacher, M; Vescia, S; von Minckwitz, G, 2010) |
| "To compare dose-intensified epirubicin monotherapy with a standard sequential regimen, patients with primary breast cancer and > or =10 involved axillary nodes were randomised to either four 21-day cycles of epirubicin 120 mg/m(2) (E120; n=202) or four 21-day cycles of epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) (EC) followed by three 28-day cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF; n=209)." | 5.14 | Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group. ( Ataseven, B; Conrad, B; Eiermann, W; Graf, E; Hilfrich, J; Kaufmann, M; Loibl, S; Massinger-Biebl, H; Schumacher, M; Vescia, S; von Minckwitz, G, 2010) |
| "Premenopausal women with breast cancer often enter a premature menopause during initial treatment of their malignancy, with resulting loss of childbearing capacity, onset of menopausal symptoms, and subsequent prolonged exposure to long-term risks of menopause." | 1.30 | Risk of menopause during the first year after breast cancer diagnosis. ( Ennis, M; Goodwin, PJ; Hood, N; Pritchard, KI; Trudeau, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pritchard, KI | 2 |
| Eiermann, W | 1 |
| Graf, E | 1 |
| Ataseven, B | 1 |
| Conrad, B | 1 |
| Hilfrich, J | 1 |
| Massinger-Biebl, H | 1 |
| Vescia, S | 1 |
| Loibl, S | 1 |
| von Minckwitz, G | 1 |
| Schumacher, M | 1 |
| Kaufmann, M | 1 |
| Goodwin, PJ | 1 |
| Ennis, M | 1 |
| Trudeau, M | 1 |
| Hood, N | 1 |
| Koyama, H | 1 |
| Wada, T | 1 |
| Nishizawa, Y | 1 |
| Iwanaga, T | 1 |
| Aoki, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms[NCT02672189] | Phase 3 | 254 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University[NCT00902720] | Phase 4 | 25 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Menopause, Premature
| Article | Year |
|---|---|
Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 2009 |
1 trial available for fluorouracil and Menopause, Premature
| Article | Year |
|---|---|
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2010 |
2 other studies available for fluorouracil and Menopause, Premature
| Article | Year |
|---|---|
Risk of menopause during the first year after breast cancer diagnosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cis | 1999 |
Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer.
Topics: Adult; Amenorrhea; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; Fluorouracil; Follicle Sti | 1977 |